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Abstract
Elevated expression of AKT has been noted in a significant percentage of primary human breast cancers, mainly as a
consequence of the PTEN/PI3K pathway deregulation. To investigate the mechanistic basis of the AKT gain of function-
dependent mechanisms of breast tumorigenesis, we explored the phenotype induced by activated AKT transgenes in a
quantitative manner. We generated several transgenic mice lines expressing different levels of constitutively active AKT in
the mammary gland. We thoroughly analyzed the preneoplastic and neoplastic mammary lesions of these mice and
correlated the process of tumorigenesis to AKT levels. Finally, we analyzed the impact that a possible senescent checkpoint
might have in the tumor promotion inhibition observed, crossing these lines to mammary specific p53(R172H) mutant
expression, and to p27 knock-out mice. We analyzed the benign, premalignant and malignant lesions extensively by
pathology and at molecular level analysing the expression of proteins involved in the PI3K/AKT pathway and in cellular
senescence. Our findings revealed an increased preneoplastic phenotype depending upon AKT signaling which was not
altered by p27 or p53 loss. However, p53 inactivation by R172H point mutation combined with myrAKT transgenic
expression significantly increased the percentage and size of mammary carcinoma observed, but was not sufficient to
promote full penetrance of the tumorigenic phenotype. Molecular analysis suggest that tumors from double
myrAKT;p53(R172H) mice result from acceleration of initiated p53(R172H) tumors and not from bypass of AKT-induced
oncogenic senescence. Our work suggests that tumors are not the consequence of the bypass of senescence in MIN. We
also show that AKT-induced oncogenic senescence is dependent of pRb but not of p53. Finally, our work also suggests that
the cooperation observed between mutant p53 and activated AKT is due to AKT-induced acceleration of mutant p53-
induced tumors. Finally, our work shows that levels of activated AKT are not essential in the induction of benign or
premalignant tumors, or in the cooperation of AKT with other tumorigenic signal such as mutant p53, once AKT pathway is
activated, the relative level of activity seems not to determine the phenotype.
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Introduction
The PTEN/PI3K pathway is one of the most altered in cancer.
PTEN activity is lost by mutations, deletions or promoter
methylation silencing at high frequency in many primary and
metastatic human cancers [1,2]. Germline mutations of PTEN are
found in Cowden, Bannayan-Riley-Ruvalcaba and a Proteus –like
syndromes, all of them familial cancer predisposition syndromes
[3,4,5,6]. The PI3KCA gene (coding for the p110a catalytic
subunit of PI3K) have been described to be highly mutated in
human tumors [2,7]. The most frequently observed PI3-kinase
mutations showed enhanced catalytic activity [8], able to
constitutively activate AKT and produce transcriptional activa-
tion. It has also been reported an AKT1 somatic mutation in
human breast, colorectal and ovarian cancers. This mutation
activates AKT by means of pathological localization to the plasma
membrane, stimulates downstream signaling, transforms cells and
induces leukemia in mice [9]. Activation without mutations of
PI3K and AKT are reported to occur in breast [10,11,12], ovarian
[11,13,14], pancreatic [15], esophageal [16], thyroid cancer [17]
and other cancers [2,18].
Loss of PTEN function, as well as PI3K activation (either by
growth factors or oncogenic mutations), results in accumulation of
PIP3 triggering the activation of its downstream effectors, PDK1
and AKT. AKT activation stimulates cell cycle progression,
survival, metabolism and migration through phosphorylation of
many physiological substrates [19] [20,21]. Deletion of AKT1
reversed the survival phenotype in PTEN null cells and abrogated
its growth advantage [22]. Similarly, inactivation of AKT by
dominant negative mutants inhibits the survival advantage
provided by activated class I PI3K [23]. Disruption of AKT1
inhibits ErbB2-induced mammary tumorigenesis [24]. AKT1
deficiency delayed tumor growth and reduced metastasis. AKT1
null mammary epithelial tumor cells have also reduced prolifer-
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ative capability with reduced cyclinD1 and increased p27 [24].
This suggests that AKT1 plays an important role in mammary
tumorigenesis.
However, these contributions to tumorigenesis come from loss
of function studies, corroborating that AKT activation is necessary
for some tumorigenic signals. However, the situation is more
complex when we try to reproduce tumorigenic phenotypes by
gain of function of AKT signal.
Targeted deletion of PTEN in the mouse leads to constitutive
activation of the PI3K/AKT pathway. Mice with a mammary-
specific deletion of the PTEN gene displayed precocious lobulo-
alveolar development, excessive ductal branching, delayed invo-
lution and severely reduced apoptosis [25]. PTEN null mammary
epithelial cells were deregulated and hyperproliferative. Homozy-
gous mutant females developed mammary tumors early in life.
The constitutive activation of p110a in the epithelial cells of the
mammary gland predisposes mammary glands to neoplastic
transformation [26]. This mild tumor phenotype was enhanced
when the mice were crossed with mice carrying an activating
mutation of cdk4. Activation of AKT into mammary epithelial
cells led to involution defects, however, non increased rate of
tumors were observed despite the high expression levels of the
constitutively active form of AKT [19,27] [28].
In this regard, complete loss of PTEN in prostate also triggers
cellular senescence which occurs through a p53-dependent
mechanism [29]. Thus, complete loss of PTEN results in an
indolent prostate cancer, due to the fact that PTEN inactivation in
the prostate triggers a p53 cellular senescence response in vivo,
thereby limiting the progression of cancer. Therefore, concomitant
or sequential prostatic loss of PTEN and p53 results in a dramatic
acceleration of prostate tumorigenesis. The rationale suggests that
a p53-dependet senescent checkpoint is inhibiting malignant
tumorigenesis in these models [30].
On the other hand, Majumder and colleagues, [31] recently
published that a p27kip1-dependent checkpoint induces senes-
cence upon AKT activation, and that the ablation of this
checkpoint, allows the progression from PIN to carcinoma.
Interestingly, p27kip1 (p27) upregulation in PIN lesions do not
depend on AKT activation but was associated with alterations in
cell polarity, architecture and adhesion molecules.
To investigate the mechanistic basis of the AKT-dependent
mechanisms of breast tumorigenesis, we have explored the
phenotype induced by activated AKT transgenes in a quantitative
manner, we also explored the possible mechanism of senescence
and the possibility that different target cells for oncogenic
activation might be in the origin of AKT-dependent tumorigen-
esis. To that end we have generated several transgenic mice lines
expressing different levels of constitutively active AKT in the
mammary gland. We thoroughly analyzed the phenotype of these
mice and correlated the process of tumorigenesis to AKT levels.
We have analyzed AKT signalling induced phenotype in
preneoplastic and neoplastic mammary lesions. Finally, to explore
the possible mechanisms underlying the diverse phenotypes we
analyzed the impact that a possible senescent checkpoint might
have in the tumor promotion inhibition observed, we crossed these
lines to p53(+/2) heterozygous mice, to mammary specific
p53(R172H) mutant expression, and to p27 knock-out mice.
Our findings revealed and increased preneoplastic phenotype
depending upon AKT signaling which is not altered by p27 or p53
loss. However, p53 inactivation by R172H point mutation
combined with myrAKT transgenic expression significantly
increased the percentage and size of mammary carcinoma
observed, however it is not sufficient to promote full penetrance
of the tumorigenic phenotype. Molecular analysis suggests that
tumors from double myrAKT;p53(R172H) mice proceed from
acceleration of initiated p53(R172H) tumors and not from bypass
of oncogenic-induced senescence induced by activated AKT.
Results
Transgenic myrAKT Lines
We generated several AKT-activated transgenic lines as
previously described [27]. The different lines present variability
in both, the levels of expression of activated AKT and the degree
of chimaerism, number of cells per duct expressing the transgene.
Out of 7 expressing transgenic lines we selected 3 of them, EA5,
EA2 and EA4 that showed different levels of AKT activation
(measured as AKT phosphorylation at S473) (Figure 1). We
quantified the value of AKT activation and observed that EA5 line
showed low AKT activation, just above the basal levels, however,
EA2 and EA4 showed at least 5–7 fold activation. Due to
chimaerism observed in most transgenic lines at difference from
knock-ins models, the ducts also expressed variable percentage of
cells expressing the transgene (Figure 1A and D). While EA5
showed low number of cells with the transgene, EA2 and EA4
presented an average of 60% cells per duct with AKT activated
(Figure 1A). We did also generate the homozygous transgenic lines
expressing two alleles of activated AKT. AKT levels increase in
such homozygous lines (Fig 1C) although they do not double the
levels of AKT activation. Similarly, homozygous lines increased
the number of cells per duct expressing the transgene (Figure 1A).
Since MMTV is activated by hormones it is known that
multiparous animals increased the levels of expression of the
transgenes driven by such promoter. Therefore, we maintained
both one colony of virgin and another colony of multiparous
females. As expected, multiparous females expressed higher levels
of activated AKT (Figure 1F) and a percentage of cells above 90%
expressing the transgene (Figure 1D). Therefore we can compare
12 different lines with different levels of AKT activation and a
different percentage of cells per duct with transgene activation.
Tumor Phenotype of Transgenic myrAKT Lines
The levels of AKT activation measured as S473 phosphorylation
were functional in all lines, since mammary gland involution was
delayed in all transgenic lines (Figure S1). However, despite genetic
(one or two alleles) of physiological (virgin or multiparous)
differences that contribute to different levels of AKT and
chimaerism, no differences in the survival of transgenic lines were
observed (Data not shown). We did not observe a statistical increase
in the number of mammary tumors in any of the transgenic lines.
An in deep analysis of the mammary glands of the animals
indicated that the transgenic lines showed an increased percentage
of intraductal mammary neoplasia (MIN) and suckling differen-
tiation (Figure 2). This increase was observed in all transgenic lines
without a clear correspondence with AKT levels or degree of
chimaerism, indicating that high levels of AKT are not essential.
Only a higher incidence of MIN in almost all transgenic lines is
correlated with no pregnancies. A few animals with tumors were
also observed, of variable type, with no statistical significance
(Figure 2).
The molecular characterization of MIN indicated that MIN
from wild type animals were different from to those arising in
transgenic mammary glands. Transgenic MIN showed increased
AKT phosphorylation and were positive for Progesterone receptor
(PR), Estrogen Receptor (ER) and Estrogen Receptor phosphor-
ylation (ER-P) (Figure S2).
The few tumors arising from transgenic animals were
histologically heterogeneous but could be grouped in two main
AKT in Mammary Tumors
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classes: adenosquamous (n = 1) and carcinomas of different types
(n = 4) (Figure 2). Staining for molecular markers showed that
carcinomas presented in general similar molecular pattern (Figure
S2). All of them showed AKT phosphorylation and increased
levels of ER, ER-P and PR. They also showed strong keratin 6
(CK6), E-cadherin and p63 staining.
Taken together our data indicated that increasing the levels of
AKT in the mammary gland was not sufficient to produce a
tumoral response in mice. Only a moderate increase in
premalignant lesions was observed, and this was independent of
the levels of AKT and the degree of chimaerism in the ductal
epithelia.
Senescence Markers
It has been proposed that the activation of AKT triggers a
senescent checkpoint blocking the progression to full grown
tumors [30,32]. Therefore, we have explored whether premalig-
nant lesions expresses senescent markers and whether these are
lost in tumors (Figure 3). MIN from myrAKT transgenes clearly
over expresses p19ARF, p21cip1 (here p21) and HP1c markers of
senescence. But these markers are maintained at similar levels in
carcinomas (Figure 3). These markers are not expressed at similar
levels in MIN from wild type animals suggesting specific
oncogenic-induced senescent signals (Figure S3). On the other
hand, p16INK4a (p16) is slightly induced in MIN from transgenic
animal and lost in carcinomas (Figure 3) suggesting that Rb
pathway may be a more important senescent checkpoint than p53
in AKT-derived tumors. To confirm this point we analyzed p53
stabilization as a correlate for p53 mutation by immunohisto-
chemistry since it has been observed that most p53 mutations
appear as strong nuclear p53 staining. Especially in p53
heterozygous mouse models, LOH generally occurs by p53
mutations. We observed that neither MIN nor macroscopic
carcinomas showed p53 stabilization reflected by the low levels of
Figure 1. Expression of AKT-P S473 in the mammary gland of nulliparous and multiparous transgenic mice. (A) Percentage of ductal
mamamry cells stained with AKT-P in heterozygous and homozygous nulliparous transgenic mice and wild-type littermates. (B) Immunohisto-
chemical detection of phosphoS473 AKT1 in mammary glands of heterozygous and homozygous nulliparous transgenic mice and wild-type
littermates. (C) Quantification of staining intensity of phosphoS473 AKT1 in mammary gland of heterozygous and homozygous nultiparous
transgenic mice and wild-type littermates. (D) Percentage of ductal mamamry cells stained with AKT-P in heterozygous multiparous transgenic mice
and wild-type littermates. (E) Immunohistochemical detection of phosphoS473 AKT1 in mammary glands of heterozygous multiparous transgenic
mice and wild-type littermates. (F) Quantification of staining intensity of phosphoS473 AKT1 in mammary gland of heterozygous multiparous
transgenic mice and wild-type littermates. The staining in epithelial cells was quantified using the NIH ImageJ software package. The difference
between transgenic and wt is displayed as relative Intensity vs wt. P-value is 0.05 (unpaired Student’s t test).
doi:10.1371/journal.pone.0009305.g001
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nuclear p53 expression, correlating with wild type p53 (Figure 3).
This result points to the existence of a tumor progression barrier
different to p53.
P27 Loss Does Not Contribute to AKT-Dependent
Tumorigenesis
To explore whether a p27-dependent checkpoint induces
senescence upon AKT activation, and that the ablation of this
checkpoint, allows the progression from MIN to carcinoma, as has
been suggested in prostate models [31], first, we checked whether
p27 was activated in benign lesions and/or lost in tumors
(adenosquamous or carcinoma) in our myrAKT mice. Immuno-
histochemistry staining showed that p27 was expressed in the
normal mammary glands of wild type and AKT mice (Figure S4).
The levels seemed increased in MIN from normal or myrAKT
mice (Figure S4), although p27 levels were similar in both cases.
However, these high p27 levels were maintained in carcinoma
from myrAKT mice (Figure S4), indicating that p27 barrier was
overcame during the process of tumorigenesis.
To complement the study whether p27 might play a role
inhibiting the growth of AKT derived tumors we expressed
myrAKT transgene into p27 hetorozygous and null backgrounds.
MyrAKT;p27(2/2) mice develop pituitary tumors early in life
and died without the possibility of studying the role of p27 absence
in the mammary gland (Data not shown). Since p27 can also act as
tumor suppressor in haploinsuficience we explored this possibility
in our myrAKT mice. MyrAKT;p27(+/2) mice died slightly
earlier than myrAKT mice, however, no mammary tumors were
observed (Not shown). The analysis of the branching of mammary
glands in these mice showed similar pattern than myrAKT,
without further progression towards the tumoral phenotype
(Figure S4). Our data suggest that although p27 might contribute
to the AKT induced senescence it is not the primary determinant
of arrest for these cells to stop growth in mammary gland.
However, given the correlative and not conclusive nature of
these results, additional studies using tissue specific deletion of p27
in AKT-activated background are necessary to further strengthen
this assertion.
P53 Mutant Expression Cooperated with AKT Activation
in the Generation of Breast Carcinoma
It has been proposed that AKT activation triggers senescence in
primary cells and that this tumor suppressor mechanism might be
dependent on the presence of p53 [29] [30]. However, our data
from MIN and tumors of myrAKT models suggest that p53
pathway is not involved in the pre to malignant progression.
Figure 2. Incidence of preneoplastic and neoplastic mammary gland lesions of transgenic mice. A, H&E of mammary gland lesions of
transgenic females expressing myrAKT: a) Cystic Dilatation/ectasia conteining proteinaceus fluid, b) Alveolar hyperplasia, c) Mammary intraepithelial
neoplasia (MIN); d) Suckling differentiation; e and f) Carcinoma; e) Adenoaquamous tumor. B, Elevated incidence of MIN in heterozygous and
homozygous virgin and multiparous females of lines EA2, EA4 and EA5. C,. Elevated incidence of suckling differentiation in heterozygous and
homozygous virgin and multiparous females of lines EA2, EA4 and EA5. D, Elevated incidence of mammary tumors in heterozygous and homozygous
virgin and multiparous females of lines EA2, EA4 and EA5. P-value is 0.05 (unpaired Student’s t test).
doi:10.1371/journal.pone.0009305.g002
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However, other tumor models, such as head and neck, show p53
and AKT cooperation in tumorigenesis [33,34].
To further explore whether this mechanism plays a role in our
experimental system, we generated mice carrying the activated
AKT transgene and the mutant p53(R172H) in the mammary
ductal epithelia by crossing the MMTV-myrAKT with the wap-
p53(R172H) line. Double heterozygous transgenes were analyzed
in deep. Neither, total survival nor survival of mice with mammary
tumors was altered in these mice (Figure 4). And the range of
preneoplastic lesions did not vary in doubles myr-
AKT;p53(R172H) from p53 mutant mice alone (Figure 4). We
observed that while p53(R172H) transgenic mice did not show
Figure 3. Expression of senescence markers in MIN and mammary tumors of myrAKT mice. Immunohistochemical staining of MIN and
tumors with p19, p21, p16, Heterechromatin 1 gamma (HP1-c) and p53. A 2006magnification was used and 4006magnification was inserted in the
corner.
doi:10.1371/journal.pone.0009305.g003
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Figure 4. Survival and characterization of alteration in mammary gland of p53R172H transgenic mice. A) Tumor-free survival curves in
p53R172H and p53R172H:myr-AKT transgenic mice. Survival curves were computed using the Kaplan-Meier product-limit method. The numbers of
mice are the following: p53R172H transgenic mice(n = 16); p53R172H:myr-AKT transgenic mice (n = 18). B) Survival of mice that have developed
mammary gland tumors. The numbers of mice are the following: p53R172H transgenic mice(n = 8); p53R172H:myr-AKT transgenic mice (n = 11). C)
Mammary gland phenotypes of the p53R172H transgenic mouse lines observed after death. Whole mammary glands of dead or sacrificed (humane
end point) mice were stained with carmine red to visualize the structure of the ducts and alveolae. Three different categories of phenotypes could be
distinguished: (1) normal structure similar to the one of involuted multiparous female mice; (2) Cystic dilation (of the ducts) of more than 4 time; (3)
increased number of ramifications and strongly increased alveolar size. Points, median of each mouse cohort. In all cases, mice with pituitary tumors
were not considered. D) Incidence of preneoplastic and neoplastic lesions in p53R172H and p53R172H:myr-AKT transgenic mice. E)
Immunohistochemical staining of MIN and tumors with p19, p21, p16, Heterechromatin 1 gamma (HP1-c) and p53. A 2006magnification was
used and 4006magnification was inserted in the corner.
doi:10.1371/journal.pone.0009305.g004
AKT in Mammary Tumors
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MIN, doubles myrAKT;p53(R172H) showed 40% mice carrying
MIN, percentage similar to the observed in virgin myrAKT
transgenic lines (Figure 4). The transgenic lines with p53(R172H)
are multiparous and the incidence of MIN in doble transgenic line
is equivalent to the virgin myrAKT mice. Identical data was
observed when myrAKT transgene was expressed in a p53(+/2)
heterozygous background in virgin females (Figure S5). Therefore,
p53 mutant does not alter the MIN to carcinoma transition in
myrAKT1 transgenics. Moreover, multiparous females that
expressed p53 mutant and myrAKT reached levels of MIN
equivalent to virgin females.
To further explore the role of p53 in AKT-dependent MIN we
compared the behavior of senescent markers p19ARF, p21 or p53
in MIN from myrAKT in wild type or p53(R172H) mutant
backgrounds (Figure 4D), or in p53(+/2) heterozygous back-
ground (Figure S6). P19ARF is increased in all lines. However, it
shows different levels among the different lines, being greatly
overexpressed in the presence of mutant p53 as expected. p21 was
equally increased in all lines while p53 showed clear staining in
both lines expressing the mutant p53(R172H).
Although we did observed a 30% p53(R172H) mice with
carcinomas, the number of mice with carcinoma in doubles
myrAKT;p53(R172H) increased to 80% (Figure 5A), tumors that
showed bigger size. While in p53(R172H) mice carcinomas
showed an average size of less than 0.03 cm3, in double
myrAKT;p53(R172H) mice, carcinomas had an average volume
of 0.2 cm3 (Figure 5B and C). Both however, showed clear p53
staining (confirming p53(R172H) mutant expression). Double
myrAKT;p53(R172H) tumors also showed activated AKT, but in
general the levels were lower than in myrAKT only tumors.
These data indicated that activated AKT cooperated with p53
mutant increasing the number and size of carcinomas but not the
number of premalignant lesions, suggesting a more aggressive
phenotype instead of a predisposition to develop a malignant
lesion. However, the number of premalignant lesions, especially
MIN, do not decrease as consequence of the transition to
carcinoma, nor the double myrAKT;p53(R172H) transgenic mice
showed full penetrance phenotype despite broad expression of
transgenes in mammary ducts. Together with the data of no
mutations in the p53, or p19ARF in tumors from myrAKT suggest
that the constitutive activation of AKT induced a senescent barrier
that is independent of p53. Therefore, the mutant p53-AKT
observed cooperation might be due to an increase in proliferation
induced by AKT activation in p53(R172H)-induced carcinomas.
To explore this possibility we compared the different tumors
arising in the different cohorts. These tumors were analyzed
immunohistologically for a set of common mammary tumor
markers and evaluated by double blind observations by 2
independent pathologists. Discrete values between 0 (no expres-
sion) and 3 (higher levels) was assigned to each tumor and the
correlation between different tumors analyzed by using the
function hcluster (package amap) of the free statistical software
R. The different tumors analyzed showed very high pathological
variability across all transgenic lines. Carcinomas and adenocar-
cinomas with different degrees of mixed, glandular, acinar or solid
pathological features were observed in all lines. No specific
morphological pattern was assigned to any genetic background
(Figure 5D). We observed that while AKT levels were very high (3)
in all myrAKT tumors, tumors from double myr-
AKT;p53(R172H) transgenic mice were more heterogeneous but
in general showed lower levels of activated AKT (Figure 5D,
Figure S7). Furthermore, ER phosphorylation but not ER
expression was associated with AKT activation in agreement with
previous results indicating the relevance of ER phosphorylation by
AKT [35] [36] [27] [26]. All tumors showed clear E-cadherin
staining as reflection of their epithelial origin. CK6, nanog, p63,
ER y PR are expressed in all myrAKT tumors but only in a very
small (aprox 20%) tumors from double myrAKT;p53(R172H),
and mostly low levels (Figure S7). However it absence in most
double myrAKT;p53(R172H) tumors correlated with the observed
in p53(R172H) induced carcinomas (Figure 5D, Figure S7).
Furthermore, p63, CK6 and nanog levels are homogeneous and
higher in myrAKT tumors while tumors with mutant p53 (from
p53(R172H) and myrAKT;p53(R172H) mouse lines) are hetero-
geneous and show lower levels of expression of these proteins.
ErbB2 (Her2, neu) overexpression is observed in 20–30%
human breast cancer [37]. In mouse models loss of PTEN function
lead to elevated erbB2 protein levels [38]. We have tested whether
in our model AKT activated transgene induced erbB2 protein.
Our data showed a few ErbB2 barely positive tumors which
correlated with no expression of ER and PR and high
hystopathological grade. Only one tumor, probably outlayer,
showed high ErbB2 positivity.
The overall picture shows that tumors from double myr-
AKT;p53(R172H) transgenic mice are more close to tumors from
p53(R172H), while tumors from myrAKT are different. However,
the number of tumors is very small and a much higher number of
tumors are necessary to analyze to further support our conclusions.
Taken together, our experiments suggest that although tumor
proliferation may be blocked by the presence of wild type p53,
p53-dependent senescence might not be the only tumor suppressor
mechanism impeding tumorigenesis in the mammary glands of
myrAKT transgenic mice. The cooperation observed between
activated AKT and mutant p53 seems to indicate that AKT
enhances the proliferation of mutant p53-induced tumors.
Discussion
Elevated expression of AKT has been noted in a significant
percentage of primary human breast cancers, mainly as a
consequence of PTEN/PI3K pathway deregulation. The
PTEN/PI3K pathway is probably the most frequently mutated
pathway in human cancer. Furthermore, tyrosine kinase mem-
brane receptors are also mutated or activated (ie: ErbB2, EGFR)
contributing to AKT deregulation in mammary tumors. Different
works analyze the necessity of the AKT signal in mammary
tumorigenesis induced by different oncogenic signals (reviewed in
[39] [40] [41]). However, the enforced AKT activation found in
most mammary tumors suggest that there is also a sufficient signal
to promote tumorigenesis. However, this point is still controversial
since mammary models do not completely recapitulate the
expected tumorigenic phenotype [39].
Several hypotheses, however, have been proposed to explain
this apparent phenomenological discrepancy. Transgenic expres-
sion of activated AKT does not reach appropriate levels to induce
tumorigenesis. Either they are too low to activate oncogenic
pathway or too high activating senescence. Enforced AKT
activation leads to p53-dependent senescence, like for PTEN loss
[29], or p27-dependent senescence [31]. Finally, It is also possible
that transgenic AKT activation does not occurs in the appropri-
ated target cell (ie: it is possible that MMTV promoter used in
most of the transgenic mouse models it is not activated in the cells
susceptible to generate a tumor).
To investigate the mechanistic basis of the AKT-dependent
mechanisms of breast tumorigenesis, we have generated several
transgenic mice lines expressing different levels of constitutively
active AKT in the mammary gland. Mice expressing activated
AKT showed an increased percentage of suckling differentiation
AKT in Mammary Tumors
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even in nulliparous females. In humans high parity has generally
been associated with low breast cancer risk in several epidemio-
logical studies [42] [43] [44]. In mice ablation of AKT1
dramatically delays mammary gland differentiation during
pregnancy and lactation and promotes apoptosis and accelerates
involution what correlates with defects in Stat5 phosphorylation
Figure 5. Incidence and characterization of mammary carcinoma in p53R172H and myrAKT;p53R172H transgenic mice. A) Incidence
of carcinomas developed by transgenic mice. B) Tumor size of carcinomas developed by transgenic mice. C) Histological characterization of
carcinomas. H&E staining of carcinomas from p53R172H (a) and myrAKT;p53R172H (b and c). Three different magnifications are shown for each tumor :
206, 1006and 4006to compare the size of the tumors and the heterogeneity between then and in one tumor. a) adenocarcinoma, b) Solid carcinoma,
c) Mixed carcinoma with acinar, glandular and squamous components. D) Heat map of the expression of several markers in carcinomas from myrAKT,
p53R172H or doubles myrAKT;p53R172H.
doi:10.1371/journal.pone.0009305.g005
AKT in Mammary Tumors
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[45]. Maybe the expression of an activated AKT promotes a
differentiation of the mammary gland that protects from tumor
development.
Moreover, we thoroughly analyzed the phenotype of these mice
and correlated to the process of tumorigenesis by either
preneoplastic or neoplastic lesions. AKT activation increased the
number of benign lesions but neither AKT activated levels or
number of cells with AKT activation in the mammary duct
correlated with lesion number. Only myrAKT multiparous
females from almost all transgenic lines showed an incidence of
benign lesions, especially premalignant MIN, lower than nullip-
arous females. These data suggest that the absence of tumors in
AKT-activated mice is not a consequence of inappropriate AKT
levels in the transgene. We can also exclude that the AKT is not
activated in the right target cells (ie: cancer prone cell) since we can
increase the number of cells per duct with AKT activation in
different lines but we can not observe a parallel increase in benign
or malignant lesions. Therefore, our results suggest the existence of
a tumor suppressor barrier that prevents tumorigenesis once AKT
is activated. Clearly, p53 and p27 dependent senescence are
mayor mechanisms proposed to achieve this goal.
To explore these mechanisms we have analyzed different
molecular markers of senescence in the benign and malignant
lesions formed in AKT-activated mice. We have found that
p19ARF, p21, p27, p16 and HP1c seems to be activated in MIN
but only p16 disappears in tumors, indicating that pRb might
constitute the senescent checkpoint which needs to be overcame in
these AKT-dependent lesions to produce tumors. Interestingly,
half of tumors containing mutant p53 also lost p16.
To further explore the relevance of p27 and p53 checkpoints,
we generated transgenes with activated AKT in p27(+/2), p53
(+/2) or p53(R172H) mutant backgrounds. Our findings revealed
that the enhanced AKT-dependent preneoplastic phenotype was
not altered by p27 reduction or p53 activity loss. However, p53
inactivation by R172H point mutation combined with myrAKT
transgenic expression significantly increased the percentage and
size of mammary carcinomas. However it was not sufficient to
promote full penetrance of the tumorigenic phenotype.
These data indicated that activated AKT cooperated with p53
mutant increasing the number and size of carcinomas but not the
number of premalignant lesions. However, the number of premalig-
nant lesions, MIN, do not decrease as consequence of the transition to
carcinoma, nor the double myrAKT;p53(R172H) transgenic mice
showed full penetrance phenotype despite broad expression of
transgenes in mammary ducts. Moreover, AKT activation in parous
females decrease the incidence of MIN, but in the presence of p53
mutant this protection was not observed. Together with the data of no
mutations in the p53 nor p19ARF in tumors from myrAKT suggest
that the constitutive activation of AKT induced a senescent barrier
that is independent of p53. Therefore, the mutant p53-AKT observed
cooperation might be due to an increase in proliferation induced by
AKT activation in p53(R172H)-induced carcinomas. The molecular
comparison of tumors from myrAKT, p53(R172H) or double
myrAKT;p53(R172H) mice suggests that myrAKT;p53(R172H)
tumors seem to proceed from p53(R172H) expressing cells and that
AKT accelerated the process of tumorigenesis, rather than from cells
with activated AKT where the p53 brake has been eliminated.
On the other hand, R172H p53 mutant, equivalent to human
R175H, is a structure defective mutant whose point mutation
determines an important conformational alteration [46]. The
presence of conformational mutants has been strongly associated
with breast cancer patients [47] [48] [49]. Mutant p53 proteins do
not represent the mere loss of wild type p53 activity, but gain new
additional oncogenic functions which contribute to the develop-
ment, maintenance and spreading of cancer [46] [50,51] [52]. It
has been shown that mutant p53 triggers different pathways that
represent the molecular basis of the gain of function activity [52].
These scenarios might favor the increase of MIN detected in
multiparous double transgenic mice that do no progress to
carcinoma due to the senescence induced by AKT independent
of p53. On the other hand, the expression of mutant p53 might
contribute to tumor initiation, while active AKT background
might contribute to tumor progression through several of the
pleiotropic effects induced by AKT activity (Reviewed in [53,54],
contributing to the large increase in size observed in carcinomas.
On the other hand, increased proliferation can also contribute to
the increased number of carcinomas by increasing carcinoma
detection.
Taken together, our experiments suggest that although tumor
proliferation may be blocked by the presence of wild type p53,
p53-dependent senescence might not be the only tumor suppressor
mechanism impeding tumorigenesis in the mammary glands of
myrAKT transgenic mice. This is confirmed by the lost of p16 in
half of tumors with mutated p53.
These data fully agree with our hypothesis that pRb might
constitute the main senescent checkpoint which needs to be
overcome in these AKT-dependent lesions to produce tumors.
This hypothesis also correlated with the works of Yu et al [55],
Landis et al [56] and Reddy et al [57] reporting the necessity of
CDK4 activity for mammary tumorigenesis. Our data point
towards loss of CDK4 inhibitor p16 is the genetic alteration in the
hyperplasia to tumor transition in the AKT activated transgene. In
fact, previous results from our group showed that activated p110a
transgenic expression in CDK4(R24C) mutant background
produces an increase in preneoplastic lesions and in tumor
formation [26].
In human breast tumors, activation of cyclin D1 is a common
event. Amplification of the gene has been detected in about 15%
of breast cancers, while overexpression of cyclin D1 at mRNA and
protein levels is seen in up to 50% of primary tumors, mostly ER-
positive and well-differentiated tumors [58] [59]. Furthermore,
joint overexpression of cyclin D and PI3K pathway activation,
either directly or indirectly through membrane receptors, is a
common event described in human tumors [60] [40,61].
Since breast cancer is notable for the high incidence of cyclin
D1 aberrations with up to 50% of tumors expressing elevated
levels of the protein (reviewed in [59] [59] [62]), we can expect to
find p16 defects among the remaining tumors. To date, there have
been reports suggesting that p16 may be affected by methylation in
primary breast cancers with quoted frequencies of 15–30% [63]
[64] [65] [66] [67] and there is a relatively high rate of LOH at
9p21 [68] [69] [63]. However, due the complex nature of the 9p21
loci containing also the p14ARF and p15INK4b tumor supressors,
it is difficult to score the true relevance of p16 in this loci loss.
Furthermore, a high number of breast cell lines show abnormal-
ities, including the spontaneously immortalized line MCF10A [65]
[70]. In HMEC, p16 silencing by promoter methylation has been
reported as one of the initial events occurring to allow cell
proliferation, contributing to alleviate senescent checkpoint [71].
In our model, cyclin D1amplification or p16 lost in breast
tumors could be equivalent in maintaining CDK4 activity and
therefore inactivating pRb checkpoint.
Taken together, our experiments suggest that although tumor
proliferation may be blocked by the presence of wild type p53,
p53-dependent senescence might not be the only tumor suppressor
mechanism impeding tumorigenesis in the mammary glands of
myrAKT transgenic mice. It seems that in this model, pRb
pathway is more important checkpoint controlling senescence.
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The cooperation observed between activated AKT and mutant
p53 seems to indicate that AKT enhances proliferation of mutant
p53-induced tumors
Materials and Methods
Ethics Statement
All animal experiments were done under the experimental
protocol approved by the Institutional Committee for Care and
Use of Animals of the Spanish National Cancer Research Centre
which complies with European legislation on the care and use of
animals, NIH guidelines for the use of laboratory animals, and
related codes of ethic practice. The ethics committee for care of
animals specifically approved this study.
Generation and Analysis of Transgenic Mice
Transgene construction is described in Blanco-Aparicio et al,
2007a. Transgenic mice were generated by the microinjection of
the 4.7 kb fragment from the digested pMMTV-myrAKT1 with
AatII+SalI, (this fragment contains the MMTV promoter,
myrAKT1 sequences and SV40 poly-adenylation signal) into the
pronucleus of single-cell embryos isolated from super-ovulated
B6/CBA mice, according to standard procedures by the
Transgenic Unit, CNIO. Embryos that survived the microinjec-
tion were implanted into pseudo-pregnant females and allowed to
develop to term. All the crosses where kept in C57BL6 genetic
background. Genotyping of the transgenic MMTV-myrAKT1
mice was performed by PCR of tail DNA. For details, see Blanco-
Aparicio et al, 2006. p53 KO mice were obtained from Jackson
laboratories. p27 were a kind gift of Dr. Manuel Serrano and
p53mutant R172H were obtain from mouse models of human
cancers consortium mouse repository.
Whole Mounts
Sacrified females (human end point) and 3 days after weaning
pregnant females were euthanized using CO2, and mammary
glands were harvested, placed on dry, silanized glass slides and
fixed overnight in 1:3:6 parts of glacial acetic acid:chloro-
form:100% ethanol. Tissues were rehydrated through successive
incubations with 70% ethanol followed by distilled water, and
stained with Carmine red alum overnight. Tissues were then
dehydrated through successive incubations in graded ethanol
followed by mixed xylenes and mounted in PermountH (Fisher
Scientific, Puerto Rico).
Histopathology and Immunohistochemistry
Mammary glands were fixed in 10% buffered formalin and
embedded in paraffin. For histopathologic analysis, they were
sectioned (2.5 mm) and stained with H&E. Slideswere baked
overnight at 55uC, deparaffinized in xylene, rehydrated, and washed
with PBS. Epitope retrieval was performed in sodium citrate (pH6.1).
Endogenous peroxide activity was quenched with 1.5% hydrogen
peroxide in methanol for 10 min and incubation (40 min) with the
primary antibodies: anti-phosphoS473AKT1 (Epitomics) diluted
1:175; anti-cytokeratin 6 (Covance) diluted 1:1000; anti p63 (Thermo
Scientific) 1:100; anti-nanog (Novus Biologicals) 1:50; anti-p27
(Thermo Scientific) diluted 1:125; anti-p19 (St Cruz Biotechnoly)
1:50; anti-p21 (Santa Cruz Biotechnology) diluted 1:350;anti erbB2
(Spring Bioscience) diluted 1:15, rabbit polyclonal anti-p53 (Novo-
castra, Newcastle, UK) diluted 1:200; anti phosphoS167ERa (New
England Biolab) diluted 1:25; anti ER alpha (Master Diagnostica)
prediluted; anti progesterone receptor (Thermo Scientific) prediluted,
anti-E-cadherin (BD Transduction Laboratories,) diluted
1:150;antip16 (St. Crz Biotechnoogy) diluted 1:75; horseradish
peroxidase goat anti-rabbit IgG (Dako) diluted 1:50; horseradish
peroxidase goat anti-mouse IgG (Jackson Immunoresearch, West
Grove, PA) diluted 1:50; horseradish peroxidase rabbit anti-goat IgG
(Dako) diluted 1:50. After incubation, immunodetection was carried
out with the peroxidase-based PAP system (DAKO) using diamino-
benzidine as substrate. Incubations omitting the specific antibody
were used as a control of the technique.
Western Blot Analysis
Total protein was extracted from snap-frozen tissues by
homogenization using a Dounce homogeneizer in 1 ml extraction
buffer (25 mM Tris, pH 7.5, 150 mM NaCl, 1% TritonX-100,
15 mM EDTA, 10 mM NaF, 2 mM TAME, 5 mM benzamide,
10 mg/ml aprotinin, 40 mg/ml bestatin, 10 mg/ml EA4, 300 mg/
ml phosphoramidon, 50 mg/ml antipain, 2.5 mM Na4P2O7,
15 mM pNPP, 1 mM DTT, 60 mM ß-glycerophosphate,
10 mg/ml leupeptine, 0.14 mg/ml chymostatin, 0.7 mg/ml pep-
statin, 1 mg/ml pefabloc and complete protease inhibitor cocktail
tablet (Roche molecular Biochemicals, Spain). Homogenates were
centrifuged at 10 000 g for 10 min at 4uC twice, and fat was
removed from the surface. Final supernatants were analyzed by
western blot as described previously (28).
Statistical Analysis
All statistics were analyzed using the SPSS statistical package
(version 13.0 for Windows). Statistical analysis of tumor–free
survival curves included calculation of Kaplan–Meier distributions
of survival of two different groups of mice and comparison by a
two-sided log-rang test. T de Student tests were conducted to test
the different levels of expression of activated myrAKT, to test the
different incidence of MIN, suckling differentiation and tumors in
all the transgenic line vs wt mice. Spearman rank tests were
conducted to test the differential incidence of epithelial and non-
epithelial tumors between the different groups of treated mice. A
P-value of ,0.05 was considered statistically significant.
Hierarchical clustering was performed using the function
hcluster (package amap) of the free statistical software R [72], as
previously reported in [73]
Supporting Information
Figure S1 Mammary gland involution is altered in transgenic
females. The regression of the mammary glands of transgenic
and wild-type littermates was determined 3 d after weaning of
the first litter. Of each mouse, a whole mount preparation,
followed by red carmine staining, was performed using the right
hind leg mammary gland, whereas sections of the left hind leg
mammary gland were stained with H&E or with the antibody
against phosphorylated AKT. For all three transgenic mouse
lines, a reduced involution of the mammary glands could be
detected, which correlated with an elevated level of AKT
phosphorylation.
Found at: doi:10.1371/journal.pone.0009305.s001 (0.95 MB PPT)
Figure S2 Molecular characterization of MIN and mammary
tumors in wt and myrAKT mice. Immunohistochemical staining
of MIN and tumors with AKT Ser473, cytokerin 6, p63,
progesterone receptor (PR), estrogen receptor alpha (ER) and
phosphoS167ER -. A 2006 magnification was used and 4006
magnification was inserted in the corner.
Found at: doi:10.1371/journal.pone.0009305.s002 (2.70 MB PPT)
Figure S3 Expression of senescence markers in MIN of wt and
myrAKT mice. Immunohistochemical staining of MIN with p19,
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p21. A 2006magnification was used and 4006magnification was
inserted in the corner.
Found at: doi:10.1371/journal.pone.0009305.s003 (0.41 MB PPT)
Figure S4 p27Kip1 is expressed in mammary gland lesions of
myrAKT mice and its lost does not promotes tumorigenesis. A)
Immunohistochemical staining with p27 of wt normal mammary
gland (a)and wt MIN (c)and myrAKT normal mammary gland (b),
myrAKTMin (d), myrAKT tumors (e,f). A 2006magnification was
used and 4006magnification was inserted in the corner B) Tumor-
free survival curves in p27KO (+/2) and p27KO (+/2):myr-AKT
transgenic mice. Survival curves were computed using the Kaplan-
Meier product-limit method. The numbers of mice are the
following: p27KO (+/): transgenic mice(n=7); p27KO (+/2):myr-
AKT transgenic mice (n=12). C) Mammary gland phenotypes of
the myr AKT and p27KO (+/2);myrAKT transgenic mouse lines
observed after death. Whole mammary glands of sacrificed (humane
end point) mice were stained with carmine red to visualize the
structure of the ducts and alveolae. Four different categories of
phenotypes could be distinguished: (1) normal structure similar to the
one of young virgin female mice; (2) Cystic dilation (of the ducts) of
more than 4 time; (3) increased number of ramifications and strongly
increased alveolar size (4) Extreme alveolar hyperproliferation
covering the space between the ducts to more than 70%. Points,
median of each mouse branching observed.
Found at: doi:10.1371/journal.pone.0009305.s004 (1.76 MB PPT)
Figure S5 Survival and characterization of alteration in
mammary gland of myrAKT transgenic mice in a heterozygous
p53 (+/2) background. A) Tumor-free survival curves of p53
(+/2), myrAKT and the double transgenic p53(+/2);myrAKT
transgenic mice. Survival curves were computed using the Kaplan-
Meier product-limit method. The numbers of mice are the
following: p53(+/2) (n = 32), p53(+/2);myr-AKT(n= 49) and
myrAKT (n= 12). B) Survival of mice that have developed
mammary gland tumors. The numbers of mice are the following:
p53(+/2)(n = 3); p53(+/2);myrAKT (n= 3). C) Incidence of
preneoplastic and neoplastic lesions in p53(+/2) and p53(+/2);myr-
AKT transgenic mice.
Found at: doi:10.1371/journal.pone.0009305.s005 (0.61 MB PPT)
Figure S6 Expression of senescence markers in MIN from
myrAKT in wild type, p53(+/2) or p53R172H background.
Immunohistochemical staining of MIN with p19, p21 and p53. A
2006 magnification was used and 4006 magnification was
inserted in the corner.
Found at: doi:10.1371/journal.pone.0009305.s006 (0.74 MB PPT)
Figure S7 Molecular characterization of carcinomas in myr-
AKT, p53R172H and myrAKT;p53R172H transgenic mice.
Immunohistochemical staining with AKT Ser473, cytokerin 6,
p63, progesterone receptor (PR), estrogen receptor alpha (ER),
phosphoS167ER, p53, nanog and E-Cadherin-. A 2006magni-
fication was used and 4006 magnification was inserted in the
corner.
Found at: doi:10.1371/journal.pone.0009305.s007 (8.57 MB PPT)
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